Data gathered: September 17
Alternative Data for Forte Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | 4 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,010 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Forte Biosciences
Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California.
| Price | $12.05 |
| Target Price | Sign up |
| Volume | 32,020 |
| Market Cap | $143M |
| Year Range | $5.25 - $19.44 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease SymposiumSeptember 14 - Yahoo |
 |
4,217 Shares in Forte Biosciences, Inc. $FBRX Purchased by AlphaQuest LLCSeptember 5 - ETF Daily News |
|
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)August 21 - ETF Daily News |
 |
Forte Biosciences (NASDAQ:FBRX) Coverage Initiated at GuggenheimAugust 20 - ETF Daily News |
High-Grade Glioma Global Clinical Trials Review 2025: Enrollment and Completion Rates in Glioma Trials WorldwideSeptember 10 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 0 | 0 | -11M | 0 | -0.960 |
| Q1 '25 | 0 | 0 | 0 | -16M | -16M | -1.119 |
| Q4 '24 | 0 | 0 | 0 | -7.2M | -7.3M | -1.170 |
| Q3 '24 | 0 | 0 | 0 | -8.4M | -8.6M | -4.540 |
| Q2 '24 | 0 | 10,000 | -10,000 | -13M | -13M | -0.270 |
Insider Transactions View All
| Riley Antony A filed to buy 30,776 shares at $5.6. November 22 '24 |
| Wagner Paul A. filed to buy 1,823,236 shares at $0.8. December 20 '23 |
| Wagner Paul A. filed to buy 1,813,236 shares at $0.7. December 15 '23 |
| Wagner Paul A. filed to buy 1,803,236 shares at $0.7. December 15 '23 |
| Wagner Paul A. filed to buy 1,792,716 shares at $0.6. December 12 '23 |
Similar companies
Read more about Forte Biosciences (FBRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Forte Biosciences?
The Market Cap of Forte Biosciences is $143M.
What is the current stock price of Forte Biosciences?
Currently, the price of one share of Forte Biosciences stock is $12.05.
How can I analyze the FBRX stock price chart for investment decisions?
The FBRX stock price chart above provides a comprehensive visual representation of Forte Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Forte Biosciences shares. Our platform offers an up-to-date FBRX stock price chart, along with technical data analysis and alternative data insights.
Does FBRX offer dividends to its shareholders?
As of our latest update, Forte Biosciences (FBRX) does not offer dividends to its shareholders. Investors interested in Forte Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Forte Biosciences?
Some of the similar stocks of Forte Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.